Singapore markets close in 4 hours 44 minutes

Exicure, Inc. (XCUR)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
0.3699+0.0199 (+5.69%)
At close: 04:00PM EDT
0.3573 -0.01 (-3.41%)
After hours: 07:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3500
Open0.3570
Bid0.3572 x 100
Ask0.3700 x 100
Day's range0.3570 - 0.3700
52-week range0.3000 - 1.5000
Volume47,374
Avg. volume305,274
Market cap3.2M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-2.1100
Earnings date12 Jul 2024 - 16 Jul 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Exicure, Inc. Reports Full Year 2023 Financial Results

    CHICAGO, June 06, 2024--Exicure, Inc. Reports Full Year 2023 Financial Results

  • Business Wire

    Exicure, Inc. Received Nasdaq Notice of a Delisting Determination

    CHICAGO, May 23, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received notice of a delisting determination (the "Staff Delisting Determination") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"). The Staff Delisting Determination notified the Company that since it has not yet filed its Form 10-K for the year ended December 31, 2023 (the "Form 10-K") per Nasdaq Listing Rule 5250(c)(1) (the "Rule") by Nasdaq’s extended deadl

  • Business Wire

    Exicure, Inc. Reports Third Quarter 2023 Financial Results

    CHICAGO, May 16, 2024--Exicure, Inc. (Nasdaq: XCUR), has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value.